CDEK
← All drugs Report issue

minocycline

Trade name: minocin

Small moleculeapproved

Approved

Jun 30, 1971

Minocycline, sold under the brand name Minocin among others, is a tetracycline antibiotic medication used to treat a number of bacterial infections such as some occurring in certain forms of pneumonia. It is generally less preferred than the tetracycline doxycycline. Minocycline is also used for the treatment of acne and rheumatoid arthritis. It is taken by mouth or applied to the skin. — Wikipedia

Clinical trial activity

256 trials · 251 clinical orgs · 34 marketing orgs

Phase 1
65
Phase 2
125
Phase 3
43
Phase 4
48

Earliest trial started Jun 1, 1996 (NCT00456677)

Timeline

1970s

  1. Jun 30, 1971

    Triax — Earliest FDA Approval

  2. Jun 30, 1971

    Triax — NDA Secondary Org

  3. Jun 30, 1971

    Triax — NDA Organization

  4. Oct 26, 1972

    Bausch Health Companies — NDA Secondary Org

  5. Oct 26, 1972

    PreCision Dermatology — NDA Secondary Org

  6. Oct 26, 1972

    Rempex Pharmaceuticals — NDA Secondary Org

  7. Oct 26, 1972

    Rempex Pharmaceuticals — Marketing Organization

1990s

  1. Jul 31, 1990

    County Line — Marketing Organization

  2. Jul 31, 1990

    Alvogen — Marketing Organization

  3. Dec 30, 1991

    Watson Pharmaceuticals — Marketing Organization

  4. Dec 30, 1991

    Teva — Marketing Organization

  5. Jan 1, 1996

    Earliest Phase 2 Sponsor(trial)

  6. Mar 23, 1999

    Impax Laboratories — Marketing Organization

2000s

  1. Nov 30, 2000

    Torrent Pharmaceuticals Limited — Marketing Organization

  2. Jan 1, 2001

    Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 2001

    Earliest Phase 3 Sponsor(trial)

  4. Feb 16, 2001

    OraPharma — NDA Secondary Org

  5. Apr 16, 2003

    Par Pharmaceuticals — Marketing Organization

  6. Apr 16, 2003

    Strides Pharma Science — Marketing Organization

  7. May 8, 2006

    Medicis — NDA Secondary Org

  8. Dec 26, 2007

    Dr. Reddy's Laboratories — Marketing Organization

  9. Mar 11, 2008

    Aurobindo Pharma — Marketing Organization

  10. Mar 17, 2009

    Barr Laboratories — Marketing Organization

  11. Aug 13, 2009

    Sandoz — Marketing Organization

  12. Aug 13, 2009

    Novartis — Marketing Organization

2010s

  1. Jul 20, 2010

    Mylan — Marketing Organization

  2. Nov 30, 2011

    Chartwell Pharmaceuticals — Marketing Organization

  3. Nov 30, 2011

    Lupin — Marketing Organization

  4. Jul 11, 2012

    Fortress Biotech — Marketing Organization

  5. Jul 11, 2012

    Sun Pharmaceuticals — NDA Secondary Org

  6. Jul 11, 2012

    Fortress Biotech — NDA Secondary Org

  7. Aug 22, 2014

    Rising Pharmaceuticals — Marketing Organization

  8. Dec 30, 2015

    Sidmak Laboratories — Marketing Organization

  9. Jan 29, 2016

    Sun Pharmaceuticals — Marketing Organization

  10. Sep 28, 2016

    Alkem Labs Ltd — Marketing Organization

  11. May 8, 2017

    Epi Health — NDA Secondary Org

  12. Nov 16, 2017

    Zydus Discovery DMCC — Marketing Organization

  13. Oct 18, 2019

    Foamix Ltd. — Marketing Organization

  14. Oct 18, 2019

    Vyne Therapeutics Inc. — Marketing Organization

2020s

  1. May 27, 2022

    Beximco — Marketing Organization

  2. Jul 22, 2022

    Nexus Pharmaceuticals — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedJun 30, 1971

Chemistry & pharmacology

Loading structure…

SMILES

CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O
Mol. weight
457.48 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral, Parenteral, Topical
Availability
Prescription Only

Oral

Yes

Parenteral

Yes

Topical

Yes

Sources

Also known as

  • (4s,4as,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
  • (4s,4as,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
  • 7-dimethylamino-6-demethyl-6-deoxytetracycline
  • 7-dimethylamino-6-demethyl-6-deoxytetracycline
  • acnamino
  • aknemin
  • aknemin
  • aknemin 50
  • arestin
  • arestin
  • ark-e021
  • blemix 100
  • blemix 50
  • cyclomin
  • cyclomin
  • dentomycin
  • dentomycin
  • dynacin
  • dynacin
  • minociclina
  • minociclina
  • minociclinum
  • minociclinum
  • minocin
  • minocin
  • minocin
  • minocin 50
  • minocin mr
  • minocin mr
  • minocyclin
  • minocyclin
  • minocycline
  • minocycline
  • minocycline
  • minocycline
  • minocycline
  • minocycline
  • minocycline
  • minocycline
  • minocycline
  • minocycline
  • minocycline hcl
  • minocycline hcl
  • minocycline hcl
  • minocycline hydrochloride
  • minocycline hydrochloride
  • minocycline hydrochloride
  • minocycline hydrochloride
  • minocyclinum
  • minocyclinum
  • minogal
  • npl-2003
  • sebomin
  • sebomin
  • sebren mr
  • solodyn
  • solodyn
  • ximino

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07298057Early Phase 1 (Phase 1)Jan 15, 2026Case Western Reserve University, OraPharma
NCT07305896N/ADec 31, 2025Jinlin University
NCT07237048Phase 2/Phase 3 (Phase 3)Nov 30, 2025Maimonides Medical Center
NCT07082855Phase 3Jul 15, 2025—
NCT06699966Phase 4Jun 30, 2025Stony Brook University
NCT07068607Phase 4Apr 1, 2025People's Liberation Army of China
NCT06246396Phase 4Oct 1, 2024Emory University, National Heart, Lung, and Blood Institute (NHLBI), University of Florida
NCT06523764Phase 4Sep 30, 2024People's Liberation Army of China
NCT06537921N/ASep 1, 2024South London and Maudsley NHS Foundation Trust, University of London
NCT06561711Phase 4Aug 21, 2024Jiao Tong University
NCT06561698Phase 4Aug 21, 2024Jiao Tong University
NCT05826912Phase 2Mar 29, 2024Department of Defense, University of California, San Francisco
NCT06120140Phase 2Mar 8, 2024—
NCT06255067Phase 2/Phase 3 (Phase 3)Feb 25, 2024Ain Shams University, Tanta University
NCT06193408Phase 2Feb 11, 2024—
NCT06201793Phase 2Jan 22, 2024Tanta University
NCT06776445Phase 1Jan 5, 2024Chongqing Medical University
NCT06603688Phase 4Nov 20, 2023People's Liberation Army of China
NCT06107725Phase 2/Phase 3 (Phase 3)Nov 1, 2023Maimonides Medical Center
NCT06307288Phase 4Oct 16, 2023Jiao Tong University
Showing 20 of 256 trials
Page 1 / 13

Organizations

Research & Development (251)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Foamix Ltd.For profit171632010
University of Texas at HoustonAcademic/Hospital141422006
National Cancer Institute (NCI)Government12022006
Jiao Tong UniversityAcademic/Hospital7522015
Tel Aviv UniversityAcademic/Hospital7542003
BioPharmXFor profit6622016
OraPharmaFor profit6532004
People's Liberation Army of ChinaGovernment6432014
University of North Carolina at Chapel HillAcademic/Hospital6342011
Government of PakistanGovernment5442006
National Eye Institute (NEI)Government5512010
National Institute of Neurological Disorders and Stroke (NINDS)Government5132003
Stanley Medical Research InstituteAcademic/Hospital5142006
University of CalgaryAcademic/Hospital5422004
University of FloridaAcademic/Hospital5432011
University of ManchesterAcademic/Hospital5132006
Xijing HospitalAcademic/Hospital5532020
Columbia UniversityAcademic/Hospital4322003
GlaxoSmithKlineFor profit4322004
Harvard UniversityAcademic/Hospital4432006
251 organizations
Page 1 / 13

Marketing (45)

OrganizationOrg typeRelationshipDate
Alkem Labs LtdFor profitMKTGSep 28, 2016
AlvogenFor profitMKTGJul 31, 1990
Aurobindo PharmaFor profitMKTGMar 11, 2008
Aurobindo PharmaFor profitSYNNov 19, 2012
Barr LaboratoriesFor profitMKTGMar 17, 2009
Bausch Health CompaniesFor profitNDA2Oct 26, 1972
BeximcoFor profitMKTGMay 27, 2022
Chartwell PharmaceuticalsFor profitMKTGNov 30, 2011
County LineFor profitMKTGJul 31, 1990
Dr. Reddy's LaboratoriesFor profitMKTGDec 26, 2007
Epi HealthFor profitNDA2May 8, 2017
Foamix Ltd.For profitMKTGOct 18, 2019
Fortress BiotechFor profitMKTGJul 11, 2012
Fortress BiotechFor profitNDA2Jul 11, 2012
Impax LaboratoriesFor profitMKTGMar 23, 1999
Impax LaboratoriesFor profitSYNFeb 3, 2009
LederleFor profitMKTG—
LupinFor profitMKTGNov 30, 2011
MedicisFor profitNDA2May 8, 2006
MylanFor profitSYNAug 22, 2014
MylanFor profitSYNJul 30, 2019
MylanFor profitSYNFeb 1, 2012
MylanFor profitMKTGJul 20, 2010
Nexus PharmaceuticalsFor profitMKTGJul 22, 2022
NovartisFor profitMKTGAug 13, 2009
OraPharmaFor profitNDA2Feb 16, 2001
Par PharmaceuticalsFor profitMKTGApr 16, 2003
PreCision DermatologyFor profitNDA2Oct 26, 1972
Rempex PharmaceuticalsFor profitNDA2Oct 26, 1972
Rempex PharmaceuticalsFor profitMKTGOct 26, 1972
Rising PharmaceuticalsFor profitMKTGAug 22, 2014
SandozFor profitMKTGAug 13, 2009
Sidmak LaboratoriesFor profitMKTGDec 30, 2015
Strides Pharma ScienceFor profitMKTGApr 16, 2003
Sun PharmaceuticalsFor profitNDA2Jul 11, 2012
Sun PharmaceuticalsFor profitSYNMay 13, 2013
Sun PharmaceuticalsFor profitMKTGJan 29, 2016
TevaFor profitMKTGDec 30, 1991
Torrent Pharmaceuticals LimitedFor profitMKTGNov 30, 2000
TriaxAcademic/HospitalNDA2Jun 30, 1971
TriaxAcademic/HospitalNDAJun 30, 1971
Vyne Therapeutics Inc.For profitMKTGOct 18, 2019
Watson PharmaceuticalsFor profitMKTGDec 30, 1991
Zydus Discovery DMCCFor profitSYNMar 2, 1992
Zydus Discovery DMCCFor profitMKTGNov 16, 2017